Three days of reckoning for checkpoint blockers
Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.
The retreat of corporate venture funding?
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
AACR 2021 preview – the early themes emerge
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
After US approval Aveo faces a monumental task
Aveo gets Fotivda over the line in the US, but the market celebration looks misplaced.
The US FDA gets tough
Tecentriq follows Opdivo, Imfinzi and Keytruda in having a US approved use knocked out.
